Watch EVFM. Know when insiders buy.
One email the day a filing lands. Free.
EVFM
Evofem Biosciences, Inc.
0.01
+0.00 +0.00%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1MP/E —DIV YIELD —FCF YIELD -44.99%REV TTM $18M +4.5%NET INCOME −$15.3MNET DEBT $10.6M52W 0.01 – 0.02SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.6M | −45.4% | 80.6% | −$2.5M | −$11M | — | -0.08 | −$3.1M | $0 | −$3.1M | Aug 14 |
| Q1 2026 · Mar 31 | $899K | +6.4% | 54.4% | −$4.6M | −$5.5M | −671.7% | -0.04 | $2.3M | $2K | $2.3M | Aug 14 |
| Q4 2025 · Dec 31derived | $9.6M | +34.6% | 72.9% | $3.3M | $2.8M | — | 0.02 | $31K | $3K | $28K | Mar 11 |
| Q3 2025 · Sep 30 | $5M | +10.1% | 81.7% | $951K | −$1.6M | — | -0.01 | $336K | $0 | $336K | Nov 13 |
| Q2 2025 · Jun 30 | $4.8M | +16.0% | 84.4% | −$1.3M | −$1.8M | −232.1% | -0.01 | −$2.9M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $845K | −76.5% | 56.8% | $327K | $956K | — | 0.00 | $560K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $7.1M | +46.8% | 78.7% | −$1M | −$3M | — | -0.02 | −$2.4M | $0 | −$2.4M | Mar 11 |
| Q3 2024 · Sep 30 | $4.5M | −12.1% | 80.7% | −$2.4M | −$2.4M | −103.6% | -0.02 | −$459K | $0 | −$459K | Nov 13 |
| Q2 2024 · Jun 30 | $4.2M | — | 81.5% | −$1.4M | $1.4M | — | 0.00 | −$1.1M | $0 | −$1.1M | Nov 13 |
| Q1 2024 · Mar 31 | $3.6M | — | 81.0% | −$2.8M | −$4.8M | — | -0.16 | $123K | $14K | $109K | Nov 13 |
| Q4 2023 · Dec 31derived | $4.8M | — | 80.3% | −$3.4M | −$2.1M | — | -0.04 | −$170K | $0 | −$170K | Mar 24 |
| Q3 2023 · Sep 30 | $5.1M | — | 63.0% | −$3.6M | $66M | — | 0.10 | −$2.4M | $0 | −$2.4M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $20.2M | 77.1% | $3.4M | $391K | 1.9% | 0.00 | −$2M | $5K | −$2M | — | — |
| FY2024 · to Dec 31 | $19.4M | 80.2% | −$7.7M | −$8.9M | -45.8% | -0.11 | −$3.9M | $14K | −$3.9M | — | — |
| FY2023 · to Dec 31 | $18.2M | 64.3% | −$17.8M | $53M | 290.8% | 0.05 | −$9M | $4K | −$9M | — | — |
| FY2022 · to Dec 31 | $16.8M | 73.8% | −$84.1M | −$76.7M | -455.5% | -167.42 | −$70.4M | $341K | −$70.8M | $18K | — |
| FY2021 · to Dec 31 | $8.2M | 50.8% | −$166.8M | −$205.2M | -2489.0% | -23.63 | −$146.7M | $2.9M | −$149.6M | $0 | — |
| FY2020 · to Dec 31 | $446K | -4.9% | −$103.6M | −$142.3M | -31907.8% | -2.12 | −$104.8M | $2.3M | −$107.1M | — | — |
Every number comes from Evofem Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.